Fintel on MSN6h
Citigroup Initiates Coverage of BioNTech SE - Depositary Receipt () (BNTX) with Buy Recommendation
Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...
BioNTech initiated with a Buy at Citi
Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...
BioNTech SE (NASDAQ:BNTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...
The Pharma Letter3d
BioNTech revenues beat forecasts despite declining
Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...
Is BioNTech SE (BNTX) The Best Immunology Stock To Buy Now?
We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...
BioNTech (NasdaqGS:BNTX) Faces Sales Decline To €2,751 Million In 2024 And Projects Lower 2025 Revenue
BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...
Benzinga.com3d
Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations
BioNTech reported Q4 earnings of €1.08 per share, beating the €0.38 consensus but down from €1.88 last year. 2025 revenue guidance of €1.7B-€2.2B trails the €2.57B consensus.
BioNTech price target lowered to $151 from $172 at Truist
Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.